I thought I'd better comment before this topic goe

Quote:

---

I thought I'd better comment before this topic goes cold. But ending animal studies is a step in the right direction. I apply basic logic to things ( because I do not posses the knowledge of Ohm20 and Mightycydy .... but I've heard lots of Mouse studies with phenomenal results fail in human studies, therefore is it very possible some test drugs fail in mouse studies but would be great drugs (AKA:LL for Glioblastoma)?

---

AI may be able to come up with purely theoretical possibilities. Using that as a basis to go straight to even phase 1 trials would end up being disastrous. It would not be able to foresee currently unknown negative interactions resulting in harm or deaths.. It could also exclude possibly useful drugs by overemphasizing possible negative interactions. Some of the same problems can result from only relying on in vitro studies. In vitro will only take a look at what happens between the drug and cells without seeing the entire biological process.

Animal studies are imperfect because they are not a perfect match to human biology. In general though the closer the animal is to humans in the evolutionary tree the better the results will be. For safety studies for pregnant women you really want to use primates as the final study before going on to humans. Even as an immunomodulator leronlimab will definitely want to go that route just because of the broad effects it has.

As far as excluding potentially useful drugs, in mouse models you want to have a model that will as closely as possible resemble human conditions. For instance mice have a much tighter blood/brain junction structure than humans. With leronlimab being a large molecule in any study involving neuronal disorders or even just brain receptor occupancy you'd want a genetically engineered mouse that mimics human blood/brain barrier permeability when under inflammatory conditions.

Quote:

---

Right to try ought to be loosen up whereas people that need it can ready get it on a timely basis!

---

Right to Try is already pretty loose. The doctor, patient and pharma company all agree than the patient gets the drug. I do think that that it should be changed from not only life threatening conditions to also include seriously disabling maladies.